Enlivex (ENLV) Profit After Tax (2013 - 2025)
Enlivex (ENLV) posted quarterly Profit After Tax of $1.2 billion for Q4 2025, up 24115.71% year-over-year from N/an in Q4 2024, and up 56474.29% quarter-over-quarter from -$2.2 million in Q3 2025.
Enlivex (ENLV) Profit After Tax (2013 - 2025) Analysis & Trends
Enlivex's Profit After Tax history runs 13 years deep, the most recent figure standing at $1.2 billion for Q4 2025.
- In Q4 2025, Profit After Tax rose 24115.71% year-over-year to $1.2 billion; the TTM figure through Dec 2025 stood at $1.2 billion (up 14147.43% YoY), while the FY2025 annual figure was $1.2 billion, up 8329.17% from the prior year.
- Profit After Tax for Q4 2025 stood at $1.2 billion, up from -$2.2 million in the prior quarter.
- The five-year high for Profit After Tax was $1.2 billion in Q4 2025, with the low at -$9.9 million in Q2 2022.
- The 5-year median for Profit After Tax is -$5.0 million (2021), against an average of $57.7 million.
- The sharpest annual moves came in 2021 and 2025: Profit After Tax plunged 430.83% in 2021, then jumped 24115.71% in 2025.
- Enlivex's Profit After Tax stood at -$4.7 million in 2021, then plunged by 51.79% to -$7.2 million in 2022, then slipped by 26.51% to -$9.1 million in 2023, then surged by 43.09% to -$5.2 million in 2024, then surged by 24115.71% to $1.2 billion in 2025.
- Business Quant data shows ENLV's Profit After Tax at $1.2 billion in Q4 2025, -$2.2 million in Q3 2025, and $1.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | -1.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Bn |
| Sep 30, 2025 | -2.21 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | -3.45 Mn |
| Dec 31, 2024 | -5.18 Mn |
| Sep 30, 2024 | -2.60 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | -4.14 Mn |
| Dec 31, 2023 | -9.10 Mn |
| Sep 30, 2023 | -5.96 Mn |
| Jun 30, 2023 | -6.79 Mn |
| Mar 31, 2023 | -7.22 Mn |
| Dec 31, 2022 | -7.19 Mn |
| Sep 30, 2022 | -5.73 Mn |
| Jun 30, 2022 | -9.91 Mn |
| Mar 31, 2022 | -8.23 Mn |
| Dec 31, 2021 | -4.74 Mn |
| Sep 30, 2021 | -3.42 Mn |
| Jun 30, 2021 | -3.11 Mn |
| Mar 31, 2021 | -5.99 Mn |